Decode the G‑BA
with MBM Future Health
Ensure that patients receive the best possible treatment.
Secure a fair reimbursement for your medicine.
Focus your resources on what truly matters in AMNOG.
Identifying the best clinical development strategy for innovative medicines is extremely challenging.
Uncertainty increases when evidence is scarce – often in rare diseases and precision medicine. What is the best value proposition for future reimbursement in Germany?
Together with you, I identify the best scenario to ensure optimum results for your medicine.
Launching a product in Germany is a critical task.
Procedures at the G-BA are complex. Decision-making authorities are difficult to understand. How to make an informed decision on your individual case with your team?
Get tailored advice on decision-making procedures at the G‑BA for your individual case.
Your unique benefits
G-BA Expertise
You benefit from my long-standing experience at the G‑BA.
Your Personal Expert
You receive advice solely from me personally.
Lean Operations
You align your efforts with G‑BA expectations.
High Value
Your resources are allocated effectively.
Orphan Drug Specialist
Operating Worldwide
About
Meriem Bouslouk-Marx, MBM Future Health
Dr. Meriem Bouslouk-Marx
First-hand experience at the G‑BA
Medicine Reimbursement Policy
Medical background
Joint Scientific Consultation
Wide Range of Therapeutic Areas
Specialisation in Orphan Drugs
Cell and Gene Therapy
International Public Health
Multilingual
Public Speaker
Coming together is a beginning.
Keeping together is progress.
Working together is success.
Henry Ford
Get in touch via LinkedIn:
